Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs
Antineoplastic Combined Chemotherapy Protocols
Proto-Oncogene Proteins c-kit
Receptor, Platelet-Derived Growth Factor beta
Taken together, our data strongly suggest that PLX3397 is superior to imatinib in the treatment of MPNSTs, and the combination of PLX3397 with a TORC1 inhibitor could provide a new therapeutic approach for the treatment of this disease.